Research location
Varna
Bulgaria, Bulgaria
Advertisement
Research activity in Varna
Bulgaria, BulgariaCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Varna
8 linked trials · page 1 of 1A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1NCT03743051 · 2019-03-05 · 1 site observation
COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01636076 · 2012-11-01 · 1 site observation
COMPLETED
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationNCT01682863 · 2012-10-01 · 1 site observation
COMPLETED
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent AsthmaNCT01609478 · 2012-08-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01604278 · 2012-05-01 · 1 site observation
COMPLETED
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a DayNCT01360021 · 2011-11-01 · 1 site observation
COMPLETED
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes PatientsNCT01257451 · 2010-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.